Growth-hormone secretagogues & GH-axis peptides
Anamorelin
Also known as ONO-7643 · Adlumiz
An orally active, non-peptide ghrelin-receptor agonist approved in Japan for cancer cachexia — the best-trialled molecule in the secretagogue class.
In 60 seconds
Approved in Japan (2021) for cancer cachexia in several tumour types; two phase 3 trials (ROMANA 1 and 2) are the core dataset. The phase 3 programme reported it was generally well tolerated; hyperglycaemia and other events were monitored.
- Two phase 3 trials measured anamorelin’s effect on lean body mass and other cachexia outcomes in advanced NSCLC.
- Meta-analysis of randomised trials of anamorelin in cancer anorexia-cachexia syndrome.
- Describes the 2021 Japanese approval and the post-approval evidence base.
Mechanism
Anamorelin binds GHS-R1a, increasing appetite signalling and GH/IGF-1 release, studied as a way to counter the muscle and weight loss of cancer anorexia-cachexia.
Research status
Approved in Japan (2021) for cancer cachexia in several tumour types; two phase 3 trials (ROMANA 1 and 2) are the core dataset.
Key studies
Two phase 3 trials measured anamorelin’s effect on lean body mass and other cachexia outcomes in advanced NSCLC.
Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials — Lancet Oncol, 2016 · PMID 26906526
Meta-analysis of randomised trials of anamorelin in cancer anorexia-cachexia syndrome.
Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis — Support Care Cancer, 2017 · PMID 28074289
Describes the 2021 Japanese approval and the post-approval evidence base.
Anamorelin in Japanese patients with cancer cachexia: an update — Curr Opin Support Palliat Care, 2023 · PMID 37389636
Safety signals in the literature
The phase 3 programme reported it was generally well tolerated; hyperglycaemia and other events were monitored. Meta-analyses summarise effects on body weight and lean mass.
Legal status (South Africa)
Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
Related compounds we stock
Not stocked yet — get notified
Tell us you want Anamorelin and we’ll email you if we add it. Requests decide what we source next.
Not stocked yet
Get notified when we add Anamorelin
One email, only when it reaches the catalogue. Every request is counted when we choose what to stock next.
Comparisons
Questions
What is Anamorelin?
An orally active, non-peptide ghrelin-receptor agonist approved in Japan for cancer cachexia — the best-trialled molecule in the secretagogue class. Anamorelin binds GHS-R1a, increasing appetite signalling and GH/IGF-1 release, studied as a way to counter the muscle and weight loss of cancer anorexia-cachexia.
What is the research status of Anamorelin?
Approved in Japan (2021) for cancer cachexia in several tumour types; two phase 3 trials (ROMANA 1 and 2) are the core dataset.
What safety signals are reported for Anamorelin?
The phase 3 programme reported it was generally well tolerated; hyperglycaemia and other events were monitored. Meta-analyses summarise effects on body weight and lean mass.
Does Living Water Labs stock Anamorelin?
Not at present. Anamorelin is profiled here for reference, with citations to the published literature. You can ask to be notified if we add it. Not a registered medicine for human use in South Africa unless SAHPRA-registered under its own name; growth-hormone secretagogues are prohibited in sport under the WADA list. Supplied, where we stock it, strictly for laboratory research.
More in GH secretagogues
Research reference only. This page summarises published literature; it is not medical advice and contains no guidance on human use. Products supplied by Living Water Labs are for laboratory research only.
